Fresenius Medical Care AG & Co. KGaA (FME.BE)
| Previous close | 35.85 |
| Open | 35.89 |
| Bid | 35.51 x 30000 |
| Ask | 36.05 x 50000 |
| Day's range | 35.70 - 36.27 |
| 52-week range | 31.04 - 49.52 |
| Volume | |
| Avg. volume | 122 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 30 July 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Institutional owners may consider drastic measures as Fresenius Medical Care AG's (ETR:FME) recent €719m drop adds to long-term losses
Key Insights Given the large stake in the stock by institutions, Fresenius Medical Care's stock price might be...
PR NewswireFresenius Medical Care takes next important step towards goal to reduce CO2 emissions in its operations
Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, has signed five virtual power purchase agreements (vPPAs) with wind and solar energy project developers in Germany and the U.S. The projects are expected to feed around 580 gigawatt hours of renewable energy into the grid, which equals up to 46 percent of FME's most recently reported global consumption. The company is thus taking an important step towards its goal of reducing emiss
ZacksReasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
